Pelareorep

ASCO 2023: Oncolytics Unleashes Revolutionary Results: BRACELET-1 Trial Harnesses Inflammatory Phenotype for Metastatic HR+/HER2- Breast Cancer with Pelareorep, Paclitaxel, and Avelumab Combo.

ASCO 2023: Oncolytics Unleashes Revolutionary Results for Breast Cancer Immunotherapy

SG Tylor

ABSTRACT NUMBER – 1012 Preclinical studies have demonstrated that the oncolytic reovirus Pelareorep can enhance the tumor microenvironment by promoting ...